Please use this identifier to cite or link to this item: https://doi.org/10.3390/antibiotics9080451
DC FieldValue
dc.titleClinical experience with high-dose polymyxin b against carbapenem-resistant gram-negative bacterial infections—a cohort study
dc.contributor.authorCai, Y.
dc.contributor.authorLeck, H.
dc.contributor.authorTan, R.W.
dc.contributor.authorTeo, J.Q.
dc.contributor.authorLim, T.-P.
dc.contributor.authorLee, W.
dc.contributor.authorChlebicki, M.P.
dc.contributor.authorKwa, A.L.
dc.date.accessioned2021-08-27T04:23:47Z
dc.date.available2021-08-27T04:23:47Z
dc.date.issued2020
dc.identifier.citationCai, Y., Leck, H., Tan, R.W., Teo, J.Q., Lim, T.-P., Lee, W., Chlebicki, M.P., Kwa, A.L. (2020). Clinical experience with high-dose polymyxin b against carbapenem-resistant gram-negative bacterial infections—a cohort study. Antibiotics 9 (8) : 1-10. ScholarBank@NUS Repository. https://doi.org/10.3390/antibiotics9080451
dc.identifier.issn2079-6382
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/199763
dc.description.abstractPopulation pharmacokinetic studies have suggested that high polymyxin B (PMB) doses (?30,000 IU/kg/day) can improve bacterial kill in carbapenem-resistant Gram-negative bacteria (CR-GNB). We aim to describe the efficacy and nephrotoxicity of patients with CR-GNB infections prescribed high-dose PMB. A single-centre cohort study was conducted from 2013 to 2016 on septic patients with CR-GNB infection and prescribed high-dose PMB (~30,000 IU/kg/day) for ?72 h. Study outcomes included 30-day mortality and acute kidney injury (AKI) development. Factors associated with AKI were identified using multivariable regression. Forty-three patients with 58 CR-GNB received high-dose PMB; 57/58 (98.3%) CR-GNB were susceptible to PMB. The median daily dose and duration of high-dose PMB were 32,051 IU/kg/day (IQR, 29,340–34,884 IU/kg/day) and 14 days (IQR, 7–28 days), respectively. Thirty-day mortality was observed in 7 (16.3%) patients. AKI was observed in 25 (58.1%) patients with a median onset of 8 days (IQR, 6–13 days). Higher daily PMB dose (aOR,1.01; 95% CI, 1.00–1.02) and higher number of concurrent nephrotoxins (aOR, 2.14; 95% CI; 1.03–4.45) were independently associated with AKI. We observed that a sizable proportion developed AKI in CR-GNB patients described high-dose PMB; hence, the potential benefits must be weighed against increased AKI risk. Concurrent nephrotoxins should be avoided to reduce nephrotoxicity. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2020
dc.subjectPharmacodynamics
dc.subjectPharmacokinetics
dc.subjectPolymyxin B nephrotoxicity
dc.subjectPolymyxins
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.3390/antibiotics9080451
dc.description.sourcetitleAntibiotics
dc.description.volume9
dc.description.issue8
dc.description.page1-10
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_antibiotics9080451.pdf551.99 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

9
checked on Jun 22, 2022

WEB OF SCIENCETM
Citations

3
checked on Oct 6, 2021

Page view(s)

69
checked on Jun 23, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons